SDSuresh Dutta

Suresh Dutta

*This is an algorithmically generated author record based on publicly available information.

Suresh Dutta has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Feasibility of tomotherapy-based image-guided radiotherapy for small cell lung cancer

    by Nam P. Nguyen, Wei Shen, Sarah Kratz, Jacqueline Vock, Paul Vos, Vinh-Hung Vincent, Gabor Altdorfer, Lars Ewell, Siyoung Jang, Ulf Karlsson, et al.

    Background: To assess the tolerance of patients with small cell lung cancer undergoing chemoradiation with tomotherapy-based image-guided radiotherapy (IGRT). Materials and methods: A retrospective review of the toxicity profile for nine patients with small cell lung cancer of the limited stage who underwent chemoradiation delivered with helical tomotherapy (HT) has been conducted. Results: Acute grade 3-4 hematologic and esophagitis toxicities developed in two and three patients respectively. One patient developed a pulmonary embolism during radiotherapy. Seven patients had weight loss ranging from 0 to 30 pounds (median: 4 pounds). Three patients had treatment breaks ranging from 2 to 12 days. At a median follow-up of 11 months (range: 2-24 months), no patients developed any radiation related toxicities such as grade 3-4 pneumonitis or other long-term complications. The median survival was estimated to be 15 months. There were 2 local recurrences, 3 mediastinal recurrences, and six distant metastases. Conclusion: Grade 3-4 toxicities remained significant during chemoradiation when radiation was delivered with tomotherapy-based IGRT. However, the absence of grade 3-4 pneumonitis is promising and the use of HT needs to be investigated in future prospective studies.


  • Open Access

    Effectiveness of prophylactic retropharyngeal lymph node irradiation in patients with locally advanced head and neck cancer

    by Nam P Nguyen, Jacqueline Vock, Vincent Vinh-Hung, Fabio Almeida, Lars Ewell, Michael Betz, Siyoung Jang, Richard A Vo, Suresh Dutta, Juan Godinez, et al.

    The aim of the study is to assess the effectiveness of intensity-modulated radiotherapy (IMRT) or image-guided radiotherapy (IGRT) for the prevention of retropharyngeal nodal recurrences in locally advanced head and neck cancer.


    • 1 November 2009
      • Vol. 29  (11) , 4683-7

    Altered glucose metabolism during chemoradiation for head and neck cancer.

    by Nam P Nguyen, Paul Vos, Vincent Vinh-Hung, Thomas L Borok, Suresh Dutta, Ulf Karlsson, Howard Lee, Tomas Martinez, Beng-Hoey Jo, Ly M Nguyen, et al.

    Platinum-based chemotherapy has been reported to induce diabetes and hyperosmolar coma in nondiabetic patients. The aim of the present study was to determine whether the administration of chemoradiation for head and neck carcinoma alters glucose metabolism during and after treatment. Weekly nonfasting serum glucose level was obtained during treatment of one hundred and six patients with locally advanced head and neck cancer who underwent chemoradiationt. For the 91 non-diabetic patients, mean serum glucose level measured 97.75 before and 102.1, 102, 104.1, 109.1, 109.7, 110.3, 109.8, 113.2, 107.7 and 104.3 mg/dl during weeks 1-10 of treatment respectively. Serum glucose level elevation reached statistical significance for weeks 5-8. Chemoradiation for head and neck cancer may produce severe glucose metabolism alteration during treatment.


    • 4 April 2008
      • Vol. 28, 431-4

    Dysphagia severity and aspiration following postoperative radiation for locally advanced oropharyngeal cancer.

    by Nam P Nguyen, Cheryl Frank, Candace C Moltz, Paul Vos, Carrie Millard, Herbert J Smith, Suresh Dutta, Howard Lee, Tomas Martinez, Ulf Karlsson, et al.

    The aim of the present study was to assess dysphagia severity following postoperative radiation for locally advanced oropharyngeal cancer. Eighteen patients with oropharyngeal carcinoma had undergone postoperative radiation. There were eight base of tongue, eight tonsils, and two soft palate carcinomas. All the patients had undergone modified barium swallow (MBS) to assess the persistence of dysphagia (more than one month) post-treatment. All the patients were cancer-free at the time of the swallowing study. Dysphagia severity was graded as 1-7. At a median follow-up of 12 months, there were three grade 2, four grade 3, two grade 4, five grade 5, two grade 6, and two grade 7. Only three patients (17%) had normal swallow post-treatment. Six patients (33%) had mild to moderate dysphagia (grade 3-4). Nine patients (50%) developed aspiration (grade 5-7). Among the patients who developed aspiration, four (22%) required tube feeding for severe aspiration. Long-term (more than one year) dysphagia following postoperative radiation for oropharyngeal cancer may be symptomatic of permanent damage to the swallowing mechanism. Evaluation of patients who complain of persistence of dysphagia a year or more following treatment should include MBS, because of the increased risk of aspiration.


    • 1 April 2008
      • Vol. 37  (2) , 219-24

    Prevalence of pharyngeal and esophageal stenosis following radiation for head and neck cancer.

    by Nam P Nguyen, Herbert J Smith, Candace C Moltz, Cheryl Frank, Carrie Millar, Suresh Dutta, Howard Lee, Debra North, Ulf Karlsson, Paul Vos, et al.

    To evaluate the risk and outcome of pharyngoesophageal stenosis in patients who complained of dysphagia following radiation for head and neck cancer. Retrospective study. Veterans Administration hospital. Patients who complained of persistent dysphagia following radiation alone or combined with surgery or chemotherapy for head and neck cancer. Patients were selected if they were cancer free at the time of the swallowing study. All patients had modified barium swallow (MBS) and an endoscopic examination for initial evaluation of their dysphagia. Traditional barium swallow was requested when there was a suspicion of pharyngoesophageal stenosis on MBS. Two hundred twenty-two patients underwent MBS for evaluation of dysphagia posttreatment. Traditional barium swallow confirmed the diagnosis of pharyngeal (n = 2) or esophageal (n = 14) stenosis in 16 patients. Eight patients had esophageal stenosis on endoscopic examination. All patients underwent dilatation for relief of their dysphagia. The number of dilatations performed was, respectively, one in 12 patients, two in 4 patients, three in 3 patients, four in 3 patients, five in one patient, and six in one patient. Pharyngeal and/or cervical esophageal stenosis may be the cause of dysphagia following radiation for head and neck cancer. Esophageal dilatations often offer temporary relief of the dysphagia.


    • 1 April 2008
      • Vol. 37  (2) , 225-9

    Risk of aspiration following radiation for non-nasopharyngeal head and neck cancer.

    by Nam P Nguyen, Cheryl Frank, Candace C Moltz, Carrie Millar, Paul Vos, Herbert J Smith, Suresh Dutta, Ulf Karlsson, Phuc D Nguyen, Ly M Nguyen, et al.

    We assessed the rate of aspiration following radiation for non-nasopharyngeal head and neck cancer. Retrospective study. Veterans Administration Hospital. Thirty-three patients who underwent radiation for head and neck cancer. Modified barium swallow was performed prior to and following treatment to assess the persistence of dysphagia and aspiration risk. All patients were cancer free at the time of the swallowing study. Dysphagia severity was graded from 1 to 7. Preradiation baseline dysphagia was observed as follows: 10 grade 1, 14 grade 2, 9 grade 3, and 1 grade 4. Following radiation, at a median follow-up of 3 months, nine patients had grade 1, eight patients had grade 2, six patients had grade 3, two patients had grade 4, three patients had grade 5, two patients had grade 6, and three patients had grade 7. Overall, 24% (8 of 33) of the patients developed aspiration (grades 5-7). Fifteen percent (5 of 33) of the patients had severe aspiration (grades 6-7) requiring tube feedings. All patients who developed severe aspiration continued to require tube feedings more than 1 year following treatment completion. Aspiration is a significant source of morbidity following radiation for non-nasopharyngeal head and neck cancer. Aspiration may develop for all tumour stages or sites. Diagnostic studies such as modified barium swallow should be included in future prospective head and neck cancer studies to assess the prevalence of aspiration because of its often silent nature.

    • 29 June 2007
      • Vol. 27, 1669-72

    Aspiration occurence during chemoradiation for head and neck cancer.

    by Nam P Nguyen, Herbert J Smith, Suresh Dutta, Alan Alfieri, Debra North, Phuc D Nguyen, Howard Lee, Tomas Martinez, Claire Lemanski, Adir Ludin, et al.

    To assess the risk of developing aspiration during chemoradiation for head and neck cancer. A retrospective review of 114 patients who underwent concurrent chemoradiation for locally advanced head and neck cancer was undertaken. Patients were determined as having aspiration if they had pneumonia on chest-X-ray (CXR) and/or had documented aspiration on the modified barium swallow (MBS) during their treatment. Fifteen patients (13%) developed aspiration during chemoradiation. Twelve patients (10%) had aspiration demonstrated on CXR alone (9 patients) or combined with MBS (3 patients). Three patients (3%) had aspiration on MBS alone. Three of the six patients with aspiration observed on MBS had normal swallowing on their pretreatment MBS. All 15 patients had severe mucositis and neutropenia at the time of the aspiration. Despite broad-spectrum antibiotics and supportive care, six patients (5%) died. Aspiration may develop during chemoradiation for head and neck cancer because of radiation-induced altered swallow.


    • 25 June 2003
      • Vol. 23, 1649-56

    Amifostine and curative intent chemoradiation for compromised cancer patients.

    by Nam P Nguyen, Barry Levinson, Suresh Dutta, Ulf Karlsson, Kevin C Kelly, Jonathan Dowell, Adir Ludin, Sabah Sallah

    Concurrent chemotherapy and radiation are usually indicated for locally advanced carcinomas such as head and neck and anal malignancies. Because of the toxicity of the treatment, patient selection plays an important role in recommendations to treat with a curative intent. Elderly patients (> 70 years), those with underlying medical conditions or acquired immunological disorders (AIDS) are commonly excluded from combined modality therapy because of their perceived inability to tolerate the aggressive treatment. They may thus be deprived of a potentially curative therapy. In an attempt to improve outcome, we conducted a pilot study using amifostine, a radioprotector, to increase the tolerance of such compromised individuals to treatment. Amifostine (500 mg intravenously) was given during chemotherapy on days 1-5, and days 21-25 of radiation regimen. All patients were able to complete the chemoradiation. Despite the locally advanced stage of the disease, five out of our six patients achieved a complete response (CR). One patient with synchronous primaries had a complete response for the base of tongue cancer and regression of the esophageal cancer, which allowed him to resume oral feeding. All patients achieved improved quality of life. Successful chemoradiation appears to be feasible in patients with advanced stage, age and/or underlying medical conditions when amifostine is integrated in the treatment.